XXXX as a predictor of cardiovascular outcomes and mortality in elderly individuals.

@entity1 @entity1095 @entity8 @entity64 @entity712 @entity177 @entity613 @entity1011 @entity65 @entity454
OBJECTIVES: This study was designed to evaluate the relationship between elevated @entity1011 levels and cardiovascular events. BACKGROUND: @entity454 is associated with high @entity65 and mortality. The association of mild to moderate @entity177 with cardiovascular outcomes remains unclear. METHODS: We analyzed data from the Cardiovascular Health Study, a prospective population-based study of subjects, aged >65 years, who had a serum @entity1011 measured at baseline (n = 5,808) and were followed for a median of 7.3 years. Proportional hazards models were used to examine the association of @entity1011 to all-cause mortality and incident cardiovascular mortality and morbidity. @entity177 was defined as a @entity1011 level > or =1.5 mg/dl in @entity1 or > or =1.3 mg/dl in @entity1 . RESULTS: An elevated @entity1011 level was present in 648 (11.2%) @entity1 . Subjects with elevated @entity1011 had higher overall (76.7 vs. 29.5/1,000 years, p < 0.001) and cardiovascular (35.8 vs. 13.0/1,000 years, p < 0.001) mortality than those with normal @entity1011 levels. They were more likely to develop @entity65 (54.0 vs. 31.8/1,000 years, p < 0.001), @entity64 (21.1 vs. 11.9/1,000 years, p < 0.001), @entity712 (38.7 vs. 17/1,000 years, p < 0.001), and symptomatic @entity1095 (10.6 vs. 3.5/1,000 years, p < 0.001). After adjusting for cardiovascular risk factors and subclinical disease measures, elevated @entity1011 remained a significant predictor of all-cause and cardiovascular mortality, total @entity65 ( @entity65 ), @entity613 , and @entity712 ( @entity712 ). A linear increase in risk was observed with increasing @entity1011 . CONCLUSIONS: Elevated @entity1011 levels are common in older adults and are associated with increased risk of mortality, @entity65 , and @entity712 . The increased risk is apparent early in @entity8 .
